| Document |
Document Title |
|
WO/2004/035599A1 |
A process for the phosphitylation of an alcohol or thiol with a phosphitylation agent in the presence of an activator is provided. The activator has the formula (1): wherein p is 0 or an integer from 1 to 4 and R for each occurrence is a...
|
|
WO/2004/031405A1 |
The present invention relates to methods of transferring a label from novel substrates to O6-alkylguanine-DNA alkyltransferases (AGT) and O6-alkylguanine-DNA alkyltransferase fusion proteins, and to novel substrates suitable in such meth...
|
|
WO2002100354B1 |
Compositions and methods for pyrrolo[2,3-d]pyrimidine nucleoside analogs having substituents at the C4' and C5' positions of the ribofuranose moiety are presented. Contemplated compositions exhibit, among other things, anti-cancer and im...
|
|
WO2003014139B1 |
The invention provides a compound that inhibits the activity of 3'-tyrosyl-DNA phophodiesterase (TDP). In one embodiment, the compound is a polynucleotide-3'- bridging phosphoramidate. The invention also provides a method of inhibiting T...
|
|
WO/2004/028454A2 |
The present invention provides compounds and methods for treatment of viral diseases and cancer.
|
|
WO/2004/028481A2 |
Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.
|
|
WO/2004/026890A1 |
The present invention is concerned with certain adenosine derivatives having an acetylene group attached in the 5' position by a linker, which are adenosine A1 agonists, and to their use in therapy.
|
|
WO/2004/027080A2 |
The present invention provides methods of extracting nucleic acids from environmental samples, such as terrestrial soil. The methods involve washing intact microbes from the sample such that humic acid is removed from the sample before t...
|
|
WO/2004/024283A2 |
Apparatus and methods are described for pharmaceutical grade manufacture extrachromosomal nucleic acids from cell lysates using flotation to separate and eliminate undesired insoluble cellular debris including chromosomal DNA from the ly...
|
|
WO/2004/024314A2 |
The present invention relates to a population of nucleic acids, said population comprising a first population of nucleic acids of the same length, said length being in the range of 5-15 nucleotides or units, said first population represe...
|
|
WO/2004/022573A2 |
Disclosed are novel adenosine A3 receptor agonists, useful for treating various disease states, including neurological and cardiac ischemia, asthma, leukopenia and neutropenia, cancer and inflammation.
|
|
WO/2004/020654A2 |
The invention relates to methods for detection of nucleic acids on a solid phase, combining high affinity and high specificity. More particularly, the invention relates to methods combining high-affinity hybridization with highly specifi...
|
|
WO/2004/018493A1 |
The invention provides a nucleotide or nucleoside having a base attached to a detectable label via a cleavable linker, characterised in that the cleavable linker contains a moiety selected from the group comprising : Formula (I) (wherein...
|
|
WO/2004/018497A2 |
The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3'-OH blocking group covalently attached thereto, such that the 3' carbo...
|
|
WO/2004/019002A2 |
Fluorescent glycosides containing aromatic hydrocarbon groups are useful in labelling and detection methods for a wide array of chemical and biological molecules. Assembly of multiple analogs to form 'polyfluors' affords fluorescence pro...
|
|
WO/2004/018496A1 |
The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5'-methylthioadenosine phosphorylases (MTAP), 5'-methylthioad...
|
|
WO/2004/018492A1 |
A new process for producing a levovirin intermediate of the formula is described. Levovirin is a nucleoside antiviral.
|
|
WO/2004/018495A1 |
A process for industrially advantageously producing either the compound represented by the following formula [I]: [I] or a pharmacologically acceptable salt of the compound, which are useful as an anticancer agent; and a hydrogenation ca...
|
|
WO/2004/018712A1 |
Oligonucleotide tagged nucleoside triphosphates, OTNTPs, which are substrates for polymerases and or terminal nucleotidyl transferases are provided as well as methods of making these OTNTPs. Further provided are OTNTPs with fluorescent d...
|
|
WO/2004/018494A1 |
A compound represented by the formula (I): (I) (wherein B is a nucleic acid base selected from the group consisting of adenine, guanine, cytosine, uracil, and hypoxanthine); a compound represented by the formula (II): (II) (wherein B' is...
|
|
WO/2004/018490A1 |
A process for substantially enhancing the regio and stereoselective synthesis of 9-β-anomeric nucleoside analogs is described. The introduction of the sugar moiety onto a 6-substituted purine base was preformed so that only the 9-β-D- ...
|
|
WO/2004/016635A2 |
Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular the supraventricular tachycardias, emesis, angina, myocardial infarction and hyperlipidemia.
|
|
WO/2004/016755A2 |
The present disclosure relates to methods for generating single-stranded DNA molecules of defined sequence and length using ligase chain reaction (LCR). Specifically, a region of template containing target sequence is amplified by LCR, e...
|
|
WO/2004/012667A2 |
Bisbipyridyl rhodium (III) compound and methods for photo-induced inactivation of pathogenic contaminants in biological materials.
|
|
WO/2004/013298A2 |
A method for the treatment or prevention of Flaviviridae infections, in particular, hepatitis C virus infection, in a host, and in particular, a human, is provided that includes administering an effective amount of a R-L- or (3-D-2',3'-d...
|
|
WO/2004/012687A2 |
Physical forms of beta-L-2'-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture...
|
|
WO/2004/012746A2 |
The present invention provides methods of treating cancer using inhibitors of inosine monophosphate dehydrogenase (IMPDH). The IMPDH inhibitors are combined with compounds that inhibit cellular processes regulated by GTP or ATP. Also pro...
|
|
WO/2004/011481A1 |
A phosmidosine derivative with excellent stability which is represented by the following general formula (I): (I) (wherein R1 represents C1-8 alkyl; R2 represents hydrogen or a nitrogen-protecting group; R3 and R4 each independently repr...
|
|
WO/2004/011480A1 |
The invention relates to a novel composition 5' choline phosphate 3'-azido 3'-deoxythymidine of formula (I) which exhibits an antiviral action, first and foremost against a human immunodefficient virus (HIV). Said composition can be prod...
|
|
WO/2004/011479A1 |
The invention herein provides novel viral DNA polymerase compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with viral DNA polymerase...
|
|
WO/2004/011681A1 |
Methods, apparatus, and a system are provided for processing a sample in a fluidic device. The device can include a purification column, an entrance opening to the purification column, an output reservoir, a fluid communication between t...
|
|
WO/2004/011478A2 |
The present invention relates generally to anti-viral compounds, particularly anti-viral 7-deaza D-nucleosides and analogues, or derivatives thereof. The invention also relates to the use of such compounds to treat or prevent hepatitis B...
|
|
WO/2004/009610A2 |
The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
|
|
WO/2004/009609A2 |
The invention encompasses nucleoside compounds, compositions comprising the compounds and methods for treating or preventing diseases associated with nonsense mutations of mRNA by administering these compounds or compositions.
|
|
WO/2004/009020A2 |
The present invention provides thionucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for ...
|
|
WO/2004/009611A2 |
Phase inversion microporous membranes including at least two different pore size regions are provided, wherein two membrane sheets are placed, back-to-back, such that the qualifying pore zones are positioned internally within the structu...
|
|
WO/2004/007751A2 |
In one aspect of the invention, a method is provided for end-labeling RNA (total RNA, mRNA, cRNA or fragmented RNA). In one embodiment, T4 RNA ligase is used to attach a 3'-biotinylated AMP or CMP donor to an RNA acceptor molecule. In an...
|
|
WO/2004/006887A2 |
Methods and pharmaceutical compositions for use in the treatment of a benign and/or a malignant proliferative pathologies are disclosed. The methods comprise administration of nicotinamide or its analogs and/or cADPR or its analogs, opti...
|
|
WO/2004/007512A2 |
The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the ...
|
|
WO/2004/007519A1 |
Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infraction.
|
|
WO/2004/007773A1 |
This invention provides methods for detecting single nucleotide polymorphisms and multiplex genotyping using dideoxynucleotides and mass spectrometry.
|
|
WO/2004/006940A1 |
A preventive/remedy for drug-induced neuropathy which contains cytidine 5’-diphosphate choline (CDP-choline) as the active ingredient. This preventive/remedy for drug-induced neuropathy has a potent effect of improving drug-induced neu...
|
|
WO/2004/005259A1 |
A drug delivery system of a substituted hydroxypyridine compound which comprises: i) orally administering the substituted hydroxypyridine compound, ii) converting the substituted hydroxypyridine compound into a conjugate during the absor...
|
|
WO/2004/002422A2 |
The 3'-L-valine ester of β-D-2'-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provide...
|
|
WO/2004/003138A2 |
The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the ...
|
|
WO/2004/002508A1 |
A method for forming arrays of metal, alloy, semiconductor or magnetic nanoparticles is described. An embodiment of the method comprises placing a scaffold on a substrate, the scaffold comprising, for example, polynucleotides and/or poly...
|
|
WO/2004/003210A2 |
Methods for preparative in vitro biocatalysis utilizing oxidoreductases. These methods are based on novel approaches to supply the oxidoreductases with reduction equivalents derived either from chemical or electrochemical sources. By uti...
|
|
WO/2004/003002A1 |
The present invention relates to compounds according to the general formula (I), wherein R1, A, B, Q, T, W and X have the meanings given in the description. These compounds are useful for the manufacture of a medicament for the treatment...
|
|
WO/2004/003001A1 |
The present invention relates to enzymatic' resolution of enantiomeric mixtures of 1,3-dioxolane-4-carboxylate esters of Formula I. More particularly, the present invention relates to a process for preparing R and S enantiomers of methyl...
|
|
WO/2004/003000A2 |
2' and 3'-Prodrugs of l', 2', 3' or 4'-branched ß-D or ß-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other rel...
|
